A detailed history of Forefront Analytics, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Forefront Analytics, LLC holds 297 shares of REGN stock, worth $208,449. This represents 0.15% of its overall portfolio holdings.

Number of Shares
297
Previous 328 9.45%
Holding current value
$208,449
Previous $344,000 9.3%
% of portfolio
0.15%
Previous 0.16%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1024.09 - $1201.76 $31,746 - $37,254
-31 Reduced 9.45%
297 $312,000
Q2 2024

Aug 14, 2024

SELL
$883.2 - $1071.19 $14,131 - $17,139
-16 Reduced 4.65%
328 $344,000
Q1 2024

May 15, 2024

BUY
$902.69 - $993.35 $22,567 - $24,833
25 Added 7.84%
344 $331,000
Q4 2023

Feb 13, 2024

BUY
$775.18 - $881.7 $20,154 - $22,924
26 Added 8.87%
319 $280,000
Q3 2023

Nov 07, 2023

SELL
$692.45 - $844.37 $33,237 - $40,529
-48 Reduced 14.08%
293 $241,000
Q2 2023

Aug 11, 2023

SELL
$700.03 - $830.35 $11,200 - $13,285
-16 Reduced 4.48%
341 $245,000
Q1 2023

May 11, 2023

BUY
$680.49 - $826.97 $34,024 - $41,348
50 Added 16.29%
357 $293,000
Q4 2022

Feb 13, 2023

SELL
$705.89 - $766.39 $5,647 - $6,131
-8 Reduced 2.54%
307 $221,000
Q3 2022

Nov 14, 2022

BUY
$573.97 - $724.32 $180,800 - $228,160
315 New
315 $216,000
Q2 2022

Aug 10, 2022

SELL
$548.35 - $738.84 $282,400 - $380,502
-515 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$595.12 - $698.43 $73,199 - $85,906
123 Added 31.38%
515 $353,000
Q4 2021

Feb 11, 2022

BUY
$543.48 - $670.97 $5,434 - $6,709
10 Added 2.62%
392 $249,000
Q3 2021

Nov 15, 2021

SELL
$574.03 - $680.96 $22,961 - $27,238
-40 Reduced 9.48%
382 $233,000
Q2 2021

Aug 10, 2021

SELL
$472.8 - $558.54 $39,242 - $46,358
-83 Reduced 16.44%
422 $235,000
Q1 2021

May 13, 2021

BUY
$446.73 - $548.2 $225,598 - $276,841
505 New
505 $238,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.2B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Forefront Analytics, LLC Portfolio

Follow Forefront Analytics, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Forefront Analytics, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Forefront Analytics, LLC with notifications on news.